Expression of macrophage colony-stimulating factor (M-CSF), interleukin-6 (IL-6), interleukin-1β (IL-1β), interleukin-11 (IL-11) and tumour necrosis factor-α (TNF-α) in p53-characterised human ovarian carcinomas

European Journal of Cancer

Volumn 33, Issue 13, 1997, Pages 2246-2251

  Asschert, J G W ^a   Vellenga, E ^a   Hollema, H ^a   Van Der Zee, A G J ^a   De Vries, E G E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Cytokine expression; Human ovarian carcinomas; P53

Indexed keywords

ANTINEOPLASTIC AGENT; COLONY STIMULATING FACTOR 1; INTERLEUKIN 11; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; PROTEIN P53; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; BLOTTING, NORTHERN; CYTOKINES; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION; HUMANS; INTERLEUKINS; MACROPHAGE COLONY-STIMULATING FACTOR; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; RNA, MESSENGER; RNA, NEOPLASM; TUMOR NECROSIS FACTOR-ALPHA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031417856     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00240-2     Document Type: Article

References (39)

1. Berchuck A, Kohler MF, Boente MP, Rodrigues GC, Whitaker BS, Bast RC. Growth regulation and transformation of ovarian epithelium. Cancer 1993, 71 (Suppl.), 545-551.
2. Boente MP, Hurteau J, Rodrigues GC, Bast RC, Berchuck A. The biology of ovarian cancer. Curr Opin Oncol 1993, 5, 900-907.
3. Moradi MM, Carson FL, Weinberg JB, Haney AF, Twiggs LB, Ramakrishnan S. Serum and ascitic fluid levels of interleukin-1, interleukin-6, and tumour necrosis factor-alpha in patients with ovarian epithelial cancer. Cancer 1993, 72, 2433-2440.
4. Lidor YJ, Xu FJ, Martinez-Maza O, et al. Constitutive production of macrophage colony-stimulating factor and interleukin-6 by human ovarian surface epithelial cells. Exp Cell Res 1993, 207, 332-339.
5. Li B-Y, Mohanray D, Olson MC, et al. Human ovarian epithelial cancer cells cultured in vitro express both interleukin-1α and β genes. Cancer Res 1992, 52, 2248-2252.
6. Guillaume T, Sekhavat M, Rubinstein DB, Hamdan O, Symann ML. Transcription of genes encoding granulocyte-macrophage colony-stimulating factor, interleukin 3, and interleukin 6 receptors and lack proliferative response to exogenous cytokines in nonhematopoietic human malignant cell lines. Cancer Res 1993, 53, 3139-3144.
7. Wu S, Boyer CM, Whitaker RS, et al. Tumour necrosis factor a as an autocrine and paracrine growth factor for ovarian cancer: Monokine induction of tumour cell proliferation and tumour necrosis factor a expression. Cancer Res 1993, 53, 1939-1944.
8. Naylor MS, Stamp GW, Foulkes WD, Eccles D, Balkwill FR. Tumour necrosis factor and its receptors in human ovarian cancer: Potential role in disease progression. J Clin Invest 1993, 91, 2194-2206.
9. Kacinsky BM, Bloodgood RS, Schwanz PE, Carter DC, Stanley ER. The macrophage colony stimulating factor CSF-1 is produced by human ovarian and endometrial adenocarcinomaderived cell lines and is present at abnormally high levels in the plasma of ovarian carcinoma patients with active disease. Cold Spring Harbor Symp Quart Biol 1989, 7, 333-337.
10. Xu FJ, Ramakrishnan S, Daly L, et al. Increased serum levels of macrophage colony stimulating factor in ovarian cancer. Am J Obstet Gynecol 1991, 165, 1356-1362.
11. Elg SA, Yu Y-H, Carson LF, et al. Serum levels of macrophage colony-stimulating factor in ovarian cancer patients undergoing second look laparotomy. Am J Obstet Gynecol 1992, 166, 134-137.
12. Berek JS, Chung C, Kaldi K, Watson JM, Knox RM, Martinez-Maza O. Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. Am J Obstet Gynecol 1991, 164, 1038-1043.
13. Van der Zee AGJ, De Cuyper EMJ, Limburg PC, et al. Higher levels of interleukin-6 in cystic fluids from patients with malignant versus benign ovarian tumours correlate with decreased hemoglobin levels and increased platelet counts. Cancer 1995, 75, 1004-1009.
14. Price FV, Chambers SK, Chambers JT, et al Colony-stimulating factor-1 in primary ascites of ovarian cancer is a significant predictor of survival. Am J Obstet Gynecol 1993, 168, 520-527.
15. Wu S, Rodabaugh K, Martinez-Maza O, et al. Stimulation of ovarian tumour cell proliferation with monocyte products including interleukin-1, interleukin-6, and tumour necrosis factor-α. Am J Obstet Gynecol 1992, 166, 997-1007.
16. Yin T, Taga T, Tsang ML-S, Yasukawa K, Kishimoto T, Yang Y-C. Involvement of IL-6 transducer gp 130 in IL-11-mediated signal transduction. J Immunol 1993, 151, 2555-2561.
17. Du XX, Williams DA. Interleukin-11: a multifunctional growth factor derived from the hematopoietic microenvironment. Blood 1994, 83, 2023-2030.
18. Marks JR, Davidoff AM, Kerns BJ, et al. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 1991, 51, 2979-2984.
19. Kohler MF, Kerns B-JM, Humphrey PA, Marks JR, Bast RC, Berchuck A. Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. Obstet Gynecol 1993, 81, 643-650.
20. Van der Zee AGJ, Hollema H, Suurmeijer AJH, et al. The value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2 and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol 1995, 13, 70-78.
21. Santhanam U, Ray A, Seghal PB. Repression of the IL-6 gene promoter by p53 and the RB susceptible gene product. Proc Natl Acad Sci USA 1991, 88, 7605-7609.
22. Margulies L, Seghal PB. Modulation of the human interleukin-6 promoter (IL-6) and transcription factor C/EBPβ (NF-IL-6) activity by p53 species. J Biol Chem 1993, 268, 15096-15100.
23. Serov SF, Scully RE, Sobin LH. Histological Typing of Ovarian Carcinomas. Geneva, World Health Organization, 1973, 17-18.
24. Sobre B, Frankendal B, Veress B. Importance of histological grade in the prognosis of epithelial ovarian carcinomas. Obstet Gynecol 1982, 59, 567-573.
25. Banks L, Matlashewski G, Crawford L. Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem 1986, 159, 529-534.
26. Vellenga E, Rambaldi A, Ernst TJ, Ostapovicz D, Griffin JD. Independent regulation of the M-CSF and G-CSF gene expression in human monocytes. Blood 1988, 71, 1529-1532.
27. Maniatis T, Fritsch EF, Sambrook J. Molecular Cloning: A Laboratory Manual. New York, Spring Harbor Laboratory, 1982, 749-750.
28. Feinberg AP, Vogelstein B. A technique for radiolabeling DNA restriction endonuclease fragments of high specific activity. Anal Biochem 1983, 132, 6-13.
29. Brakenhoff JPJ, Groot ER, Pannekoek H, Aarden LA. Molecular cloning and expression of hybridoma growth factor in E. coli. J Immunol 1987, 139, 4116-4121.
30. Watson JM, Sensintaffar JL, Berek JS, Martinez-Maza O. Constitutive production of interleukin 6 by ovarian cancer cell lines and by ovarian tumour cultures. Cancer Res 1990, 50, 6959-6965.
31. Dokter WHA, Dijkstra AJ, Koopmans SB, et al. G(Anh)MTetra, a natural bacterial cell wall breakdown product, induces interleukin-1β and interleukin-6 expression in human monocytes. J Biol Chem 1994, 269, 4201-4206.
32. Rogel A, Popliker M, Webb CG, Oren M. p53 cellular tumour antigen: analysis of mRNA levels in normal adult tissues, embryos, and tumours. Mol Cell Biol 1985, 5, 2851-2855.
33. Levine AJ, Nomand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991, 342, 705-708.
34. Midgley CA, Fisher CJ, Bârtek J, Vojtèsek B, Lane D, Barnes DB. Analysis of p53 expression in human tumours: an antibody raised against human p53 expressed in Escherichia coli. J Cell Sci 1992, 101, 183-189.
35. Yaginuma Y, Weatphal H. Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. Cancer Res 1992, 52, 4196-4199.
36. Le Clair KP, Blanar MA, Sharp PA. The p50 subunit of NF-KB associates with the NF-IL6 transcription factor. Proc Natl Acad Sci USA 1992, 89, 8145-8149.
37. Yamada H, Iwase S, Mohn M, Kufe D. Involvement of a nuclear factor-KB-like protein in induction of the macrophage colonystimulating factor gene by rumour necrosis factor. Blood 1991, 78, 1988-1995.
38. Mizutani Y, Bonavida B. Overcoming cis-diamminedichloroplatinum (II) resistance of human ovarian tumor cells by combination treatment with m-diamminedichloroplatinum (II) and tumor necrosis factor-alpha. Cancer 1993, 72, 809-818.
39. Uslu R, Bonavida B. Involvement of the mitochondrion respiratory chain in the synergy achieved by treatment of human ovarian carcinoma cell lines with both tumor necrosis factor-α and cis-diamminedichloroplatinum. Cancer 1996, 77, 725-732.